Franklin Biotechnology Discovery’s veteran managers and strong recent results inspire some confidence, but limited research support and an undifferentiated process limit its appeal.
Franklin Biotechnology Discovery Fund Class A FBDIX
- NAV / 1-Day Return 181.94 / −0.39 %
- Total Assets 1.1B
-
Adj. Expense Ratio
1.010%
- Expense Ratio 1.010%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 1.74%
- Turnover 38%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBDIX
Will FBDIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 36.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Jazz Pharmaceuticals PLC | 5.06 | 62M | Healthcare |
Amgen Inc | 4.65 | 57M | Healthcare |
argenx SE ADR | 4.15 | 51M | Healthcare |
Gilead Sciences Inc | 4.11 | 50M | Healthcare |
Vertex Pharmaceuticals Inc | 3.83 | 47M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.74 | 46M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.13 | 38M | Healthcare |
AstraZeneca PLC | 2.72 | 33M | Healthcare |
Ascendis Pharma AS | 2.68 | 33M | Healthcare |
Amylyx Pharmaceuticals Inc | 2.57 | 31M | Healthcare |